Nephrology – Page 4

Acute Kidney Injury in Extremely Preterm Infants Predicts Higher Risk of Death or Neurodevelopmental Impairment at Two Years

By MedXY 11/19/2025

Secondary analysis of the PENUT trial found that acute kidney injury (AKI) in infants born at 24–27 weeks’ gestation is independently associated with death or moderate to severe neurodevelopmental impairment at 22–26 months' corrected age.

Nephrology news Public Health

Temporary Inpatient Hemodialysis Access for Uninsured Patients Is Associated with Shorter Hospital Stays in a County Safety-Net System

By MedXY 11/19/2025

A Los Angeles County quality-improvement study found that regulatory approval allowing an inpatient hemodialysis unit to provide transitional outpatient dialysis to uninsured patients initiating hemodialysis was associated with a substantial, sustained reduction in hospital length of stay.

Nephrology news

Community Health Workers Reduce Interdialytic Weight Gain and Improve Engagement Among Hispanic/Latino Hemodialysis Patients: Results from the Navigate‑Kidney RCT

By MedXY 11/18/2025

A randomized trial found that a culturally tailored community health worker (CHW) intervention modestly reduced interdialytic weight gain, improved dialysis adherence, and increased patient activation among Hispanic and Latino adults receiving in‑center hemodialysis.

Internal Medicine Nephrology news

The Vanishing Female Survival Advantage in Stage 5 CKD: Higher Mortality and Lower Receipt of Kidney Replacement Therapy Among Women

By MedXY 11/17/2025

In a population-based Alberta cohort, women with incident stage 5 CKD lost the usual female survival advantage: younger women had substantially higher excess mortality than men and were less likely to receive transplants or dialysis, independent of comorbidity.

Internal Medicine Nephrology news

Clinical Decision Support Tool May Improve ACEI and ARB Use in CKD

By MedXY 11/14/2025

A personalized clinical decision support tool increased 30‑day reinitiation of ACE inhibitors or ARBs from 13% to 18% among veterans with CKD; benefits were modest and limited by population and implementation factors.

Nephrology news

Albuminuria Reduction and GFR Total-Slope Strongly Predict Kidney Failure: Surrogate Endpoints in CKD Trials

By MedXY 11/13/2025

Large individual-patient meta-analyses show that 6-month albuminuria reduction and 3-year total GFR slope predict kidney failure across CKD populations—supporting their use as surrogate endpoints in randomized trials with caveats for chronic slope and disease severity.

Nephrology news

Global CKD Now Affects 788 Million Adults (1990–2023): Rising Prevalence, Growing Mortality, and a Major Cardiovascular Risk

By MedXY 11/11/2025

The GBD 2023 analysis estimates 788 million adults living with chronic kidney disease in 2023, rising since 1990, with CKD a top-10 cause of death and a major contributor to cardiovascular mortality. Urgent action on screening, prevention, and treatment is needed.

Nephrology news

Atacicept Cuts Proteinuria in IgA Nephropathy — How Emerging B‑cell and Complement‑Targeted Therapies Compare

By MedXY 11/10/2025

A prespecified interim analysis of a phase 3 trial shows atacicept produced a 45.7% proteinuria reduction versus 6.8% with placebo at 36 weeks. Phase 2 data for sibeprenlimab, cemdisiran, and felzartamab also show promising antiproteinuric effects but need confirmatory outcomes.

Cardiology Nephrology news Rehabilitation Medicine

Fish-Oil Supplementation Halves Serious Cardiovascular Events in Hemodialysis Patients: Results from the PISCES Randomized Trial

By MedXY 11/10/2025

A double-blind randomized trial (PISCES) found daily fish-oil (EPA+DHA) 4 g reduced serious cardiovascular events by 43% versus corn-oil placebo in patients on maintenance hemodialysis over 3.5 years.

Diabetes & Endocrinology Nephrology news

Finerenone Lowers Albuminuria in Type 1 Diabetes with CKD: FINE‑ONE Phase III Shows 25% Average UACR Reduction and Acceptable Safety

By MedXY 11/09/2025

The FINE‑ONE Phase III trial found finerenone reduced urinary albumin-to-creatinine ratio (UACR) by 25% versus placebo in adults with type 1 diabetes and chronic kidney disease over six months, with safety broadly consistent with prior type 2 diabetes trials and a manageable hyperkalemia signal.

Diabetes & Endocrinology Nephrology news

SGLT2 Inhibitors Reduce Kidney Events, Hospitalization and Death Regardless of Diabetes or Albuminuria: A SMART-C Meta-Analysis Interpretation

By MedXY 11/08/2025

A pooled analysis of 58,816 participants shows SGLT2 inhibitors lower kidney disease progression, AKI, hospitalizations, and mortality across diabetes status and albuminuria levels, with larger absolute kidney benefits where UACR ≥200 mg/g.

Critical Care Nephrology news

Conservative Dialysis Strategy Accelerates Kidney Recovery in Dialysis-Requiring AKI — Early Randomized Evidence from LIBERATE-D

By MedXY 11/08/2025

The LIBERATE-D randomized trial found that a conservative, indication-triggered dialysis strategy increased unadjusted kidney-recovery rates at hospital discharge and shortened time to dialysis independence compared with routine thrice-weekly dialysis in patients with dialysis-requiring AKI.

Cardiology Nephrology news

When Cystatin C Says the Kidneys Are Worse: Discordant eGFR and High Risk — Findings from 860,000+ Patients

By MedXY 11/08/2025

A CKD-PC individual-patient meta-analysis found that 11% of outpatients and 35% of inpatients had eGFR by cystatin C ≥30% lower than creatinine-based eGFR; this discordance predicted higher mortality, cardiovascular events, heart failure and kidney failure.

Nephrology news

A‑E‑I‑O‑U and Sometimes Why—Dialysis in Acute Kidney Injury

By MedXY 11/08/2025

LIBERATE‑D randomized hemodynamically stable patients with AKI to conservative vs conventional thrice‑weekly continuation of KRT; conservative discontinuation increased dialysis‑free recovery, shortened time to recovery, and reduced sessions without detectable harm, challenging automatic thrice‑weekly schedules.

Diabetes & Endocrinology Nephrology news

SGLT2 Inhibitors Protect Kidneys Across the Spectrum: Benefits Even in Stage 4 CKD and Minimal Albuminuria

By MedXY 11/08/2025

A SMART‑C meta‑analysis of 70,361 participants shows SGLT2 inhibitors reduce CKD progression and kidney failure across eGFR and albuminuria strata, including stage 4 CKD and low albuminuria.

Critical Care Nephrology news

A 250‑ml Ultrafiltration Challenge Identifies Patients at Risk of Becoming Preload‑Dependent During CRRT

By MedXY 11/07/2025

A randomized cross‑over trial found that a 250‑ml net ultrafiltration challenge reliably identified preload‑independent critically ill patients who became preload‑dependent during continuous renal replacement therapy; a ≥5% calibrated cardiac index change during a postural maneuver predicted this risk.

Nephrology news

Rituximab Markedly Reduces Relapse in Adult Relapsing Nephrotic Syndrome: Randomized Trial Data from Japan

By MedXY 11/07/2025

A multicenter randomized trial in Japan found that rituximab significantly increased 49‑week relapse‑free survival versus placebo in adults with frequently relapsing or steroid‑dependent nephrotic syndrome, though infusion reactions were common and longer follow‑up is needed.

Critical Care Nephrology news

Sodium Bicarbonate in Severe Metabolic Acidemia with AKI: No Survival Benefit but Less Dialysis — Insights from BICARICU-2

By MedXY 11/07/2025

The BICARICU-2 randomized trial found that intravenous sodium bicarbonate in patients with severe metabolic acidemia and moderate-to-severe acute kidney injury did not reduce 90‑day mortality, but was associated with a substantial reduction in use of kidney replacement therapy.

Critical Care Nephrology news

Choice of Vasopressor in Septic Shock: Does It Change Kidney Outcomes? A Critical Appraisal of the Evidence

By MedXY 11/07/2025

A systematic review of 17 randomized trials (n=4,259) found no consistent renoprotective effect from any vasopressor in septic shock. Heterogeneous definitions, underpowered studies, and reliance on RRT limit conclusions; standardized renal endpoints and focused trials are needed.

$Adjunctive Terlipressin in Refractory Septic Shock: Lowers High-Dose Catecholamine Need at 6 Hours but No Mortality Benefit$

Critical Care Nephrology news

Adjunctive Terlipressin in Refractory Septic Shock: Lowers High-Dose Catecholamine Need at 6 Hours but No Mortality Benefit

By MedXY 11/07/2025

In a double-blind RCT of 130 patients with refractory septic shock, terlipressin increased the proportion achieving MAP ≥65 mmHg with low catecholamine exposure at 6 hours versus placebo but did not change 28-day mortality; digital ischemia rates were high in both groups.